Sign inJoin waitlistJoin the waitlist

Assuntina Sacco

Professor of Medicine · University of California (San Diego) Medical Center

Credentials: · · · · ·

History

University of California (San Diego) Medical Center
Present

Medical Oncology
2011–2013
Internal Medicine
2008–2011
Loyola University Chicago Stritch School of Medicine
2004–2008

Research

Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Review · Journal of Clinical Oncology · 2015 · First of 2 authors · 281 citations
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial
The Lancet Oncology · 2021 · First of 19 authors · Corresponding · 228 citations
Positive Surgical Margins in the 10 Most Common Solid Cancers
Scientific Reports · 2018 · 224 citations

DC
Douglas Chepeha
12 papers
Mark Prince
10 papers
Carol Bradford
9 papers
GW
Gregory Wolf
9 papers
JM
Jeffrey Moyer
9 papers
AE
Avraham Eisbruch
8 papers
Ezra Cohen
8 papers
FW
Francis Worden
8 papers
Loren Mell
8 papers
Joseph Califano
5 papers
Douglas Adkins
4 papers
EC
Eric Chanowski
4 papers · 2 as a resident

Grants

Targeting the Hippo-YAP/TEAD Signaling Network in Head and Neck Cancer
National Cancer Institute · R01
PI · $694.6K · University of California, San Diego
2026–2031
Targeting Systems Vulnerabilities in the EGFR/HER3/HER2 Oncogenic Signaling Circuitry: New Precision Therapies for Oral Cancer
National Institute of Dental and Craniofacial Research · R01
PI · $969.8K · University of California, San Diego
2025–2030

Clinical trials

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Principal investigator · Completed · Phase 2
University of California, San Diego
2017–2025
Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
Principal investigator · Terminated · Phase 2
Assuntina Sacco, M.D.
2017–2019
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
Study director · Active not recruiting · Phase 2
Assuntina G. Sacco, MD
2016–2026
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Site PI · Not yet recruiting · Phase 3
Corbus Pharmaceuticals Inc.
2026–2029